Home » Topics » Regulatory » EMA

EMA
RSS

Roche reports on third quarter of 2010

Nov. 18, 2010

EMA approves Cell Therapeutics' pediatric investigation plan for Pixuvri

Nov. 17, 2010

EMA orphan drug status for SBC-102 in LAL deficiency / News in Context

Nov. 17, 2010

EMA committee recommends orphan drug status for ThermoDox in primary liver cancer

Nov. 12, 2010

Schering-Plough Europe withdraws MAA for Zenhale

Nov. 11, 2010

MabThera approved in E.U. as maintenance treatment of follicular lymphoma

Nov. 4, 2010

Genta receives EMA advice for phase III tesetaxel trial in gastric cancer

Nov. 3, 2010

E.U. grants authorization for Ruconest in hereditary angioedema

Oct. 29, 2010

EMA recommends changes in prescribing information for Invirase

Oct. 26, 2010

CHMP recommends new indication for Bristol-Myers Squibb's Sprycel

Oct. 26, 2010

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...